Glimcus-MV 2 Tablet SR is a combination oral antidiabetic medication containing Glimepiride 2mg, Metformin 500mg, and Voglibose 0.2mg, designed for the management of type 2 diabetes mellitus. Glimepiride, a sulfonylurea class agent, stimulates pancreatic beta cells to enhance insulin secretion, thereby reducing blood glucose levels. Metformin, a biguanide, improves insulin sensitivity in peripheral tissues and decreases hepatic glucose production, contributing to better glycemic control. Voglibose, an alpha-glucosidase inhibitor, delays carbohydrate absorption from the gastrointestinal tract, minimizing postprandial hyperglycemia. The sustained-release formulation ensures a gradual and prolonged drug release, optimizing therapeutic efficacy while minimizing gastrointestinal side effects commonly associated with Metformin and Voglibose. Glimcus-MV 2 Tablet SR is indicated for patients inadequately controlled by diet, exercise, and monotherapy, offering a multifaceted approach to glycemic regulation. It should be administered under medical supervision, with dosage adjustments based on patient response and tolerability. Regular monitoring of blood glucose levels, renal function, and potential adverse effects such as hypoglycemia, gastrointestinal discomfort, or lactic acidosis is recommended. This combination therapy supports improved glycemic control, reducing the risk of diabetes-related complications when used as part of a comprehensive diabetes management plan.